fourth quarter beat margin improv tripl combo set
wednesday januari market close vertex report fourth quarter full
year financi result cystic fibrosi cf franchis sale came estim
manag guid lower non-gaap sg expens bottom line
non-gaap net incom quarter million per share beat
estim million per share consensu estim million
per share exhibit compani end year approxim billion
cash cash equival oper margin compani continu
grow top line rein expens expect oper margin continu improv
compani also announc initi phase ii result two tripl combin studi
evalu next-gener corrector het/min patient
demonstr impress result increas reach accompani
substanti sweat chlorid declin respiratori function improv highest
magnitud seen cf regimen date appar good safeti profil
compani elect move two corrector phase tripl combin trial
begin tez/iva first half follow tezacaftor
second tripl combo repres once-daili regimen tripl combo
pois transform care cf popul set high bar competit
come
excit scientif medic breakthrough led vertex pois
solv cf problem market perform thesi vertex share sole base
view competit market dynam maintain market perform rate
increas fair valu estim vertex share exhibit base
chang model detail herein lower tax rate
vertex initi phase studi tripl combo earli proof-of-concept data
galapago glpg outperform well proteostasi pti
tripl combo also read throughout competitor data par
vertex tripl combo vertex share might neg affect data
match vertex triple-combo profil expect vertex share appreci
return equiti ttm
biopharmaceut compani focus develop commerci therapi
cystic fibrosi compani lead asset kalydeco kalydeco lumacaftor combo registr next-
gener combin clinic develop
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
wednesday januari market close vertex report fourth quarter full year financi result cystic
fibrosi cf franchis sale came estim manag guid lower non-gaap sg
expens bottom line non-gaap net incom quarter million per share beat
estim million per share consensu estim million per share
exhibit orkambi sale approxim million estim million beat
consensu million kalydeco sale fourth quarter approxim million higher
estim consensu million full year cf revenu total billion compris
million net revenu kalydeco billion orkambi non-gaap net incom million
per share compar estim million per share consensu estim million
per share compani end year approxim billion cash cash equival oper margin
vertex continu grow top line rein expens expect oper margin continu
compani also announc initi phase ii result two tripl combin studi evalu next-gener
corrector het/min patient demonstr impress result increas
reach accompani substanti sweat chlorid declin respiratori function improv
highest magnitud seen cf regimen date appar good safeti profil compani
elect move two corrector phase tripl combin trial begin tez/iva first
half follow tezacaftor second tripl combo repres once-daili
regimen tripl combo pois transform care cf popul set high bar
competit come phase ii trial evalu tripl combin compris base duo tez/iva next-
gener corrector versu placebo cf patient four week data releas cohort cf
patient harbor one mutat one allel minimum function mutat het/min
repres total cf popul current disease-modifi treatment option
tripl combin show best efficaci observ cf regimen mutat date
combin show absolut chang percent predict increas highest
dose test exhibit substanti reduct sweat chlorid exhibit signific improv
patient-report qualiti life score effect observ earli week sustain
end four-week studi durat note vitro assay tripl combo het/min hbe human
bronchial epitheli cell abl restor cftr function zero around wildtyp higher
wildtyp function restor achiev kalydeco gate mutat hbe cell achiev
orkambi homozyg cell far vitro efficaci translat well clinic
increas tripl combo het/min patient stronger achiev kalydeco
patient week versu baselin achiev orkambi homozyg patient
correspondingli sweat chlorid reduct respiratori score achiev tripl also highest
observ date clinic trial translat dramat improv long-term outcom
safeti side combin gener well toler advers event report mild
moder sever note one discontinu mg group studi
occur last day dose due increas bilirubin without concurr increas transaminas
level also low incid sever rash one case studi resolv
discontinu one studi result dose interrupt eventu resolv
patient complet studi without incid importantli report
bronchoconstrict observ orkambi
overal believ result promis continu support vertex posit leader cf field
bring compani closer toward deliv high promis disease-modifi treatment
address total cf popul addit phase ii result combin
homozyg patient phase ii studi tripl combin tezacaftor het/min patient
expect first half compar first two second-gener corrector
two chosen corrector appear compar better efficaci like better safeti profil
step phase initi tez/iva first half follow tezacaftor
follow strong result demonstr phase ii vertex advanc
phase tripl combin studi next-gen corrector allow potenti once-daili dose compani
wrap discuss fda final studi design plan move forward first tez/iva
first half year evalu combin two separ studi het/min homozyg
patient pend addit data compani phase ii studi tezacaftor deuter
version kalydeco licens allow once-daili dose vertex
begin phase studi second tripl combo het/min homozyg patient around
excit scientif medic breakthrough led vertex pois solv cf
problem market perform thesi vertex share sole base view competit market dynam
newli releas tripl combo data set high bar competit maintain market perform rate
increas fair valu estim vertex share exhibit base follow rational
chang model lower tax rate vertex initi phase studi tripl combo
earli proof-of-concept data galapago partner proteostasi tripl combo also read
throughout competitor data par vertex tripl combo vertex share might neg affect
data match vertex triple-combo profil expect vertex share appreci
modifi cf market model give vertex peak market share
previous maintain estim competitor entri cf popul larg
alreadi identifi estim rel rapid uptak tripl combin evidenc kalydeco reach
close penetr unit state three quarter launch estim global market cf
modul peak billion declin billion ad competit drive net
price exhibit continu estim probabl vertex success launch tripl
combin billion peak global sale previou estim million
declin thereaft billion global sale last year model franchis valid patent
term bell-shap cash flow curv constitut basi valuat market perform rate
project full year non-gaap sg expens billion lower previou
estim billion manag guid non-gaap oper expens billion billion
exclud cost revenu adjust model fall within guid rang
remov model million estim royalti revenu manag note go
forward royalti revenu recogn retain earn adjust model reflect
slightli rais cog estim previous account
increas royalti paid revenu cog estim remain rel flat beyond
junctur maintain previou project kalydeco revenu million
estim combin revenu duo combo regimen orkambi tez/iva billion mostli
satur avail market expect see signific growth kalydeco go forward note
kalydeco phase test children year old carri cf mutat
drug current approv kalydeco prove safe effect popul would add roughli
children address popul data studi estim come second half tez/iva
expect see fda approv pdufa date februari manag provid
detail guidanc cf sale
base chang ep estim lower
npv model valu compani cf franchis per share togeth net cash
per share end deriv fair valu vertex share exhibit note
model includ valu program cf gene therapi program outsid cf program
remain upsid valuat
competit pursuit galapago partner recent begun test differ tripl combin
clinic first data expect summer although continu believ vertex highest
chanc success push first tripl combo market also note competit far behind particular
note galapago partner recent began clinic test tripl combin program compani
potenti candid corrector candid candid includ
potenti long half-lif one month may may optim combin other
once-daili regimen second potenti like better choic go forward recent announc data
corrector demonstr compar efficaci tezacaftor serv backbon compon
investig tripl combin corrector appear potent frontrunn
phase studi still on-going first tripl combo slate enter clinic treat cf patient
first quarter month durat test interim data expect around second tripl combo
incorpor better potenti recent begun evalu healthi volunt test
cf patient schedul begin first half third tripl combo could optim one consist
could start around data earli estim program
month behind vertex believ galapago plan path tripl combo face much higher
hurdl compar vertex tripl combo strategi trivial put three compound limit human
experi togeth success first tri note three tripl combo design once-daili dose
proteostasi begin test tripl combin cf patient begin first half initi
data follow second half year proteostasiss lead candid novel amplifi candid
design increas cftr mrna transcript phase ii trial examin mg qd day top
orkambi demonstr statist signific mean absolut improv mean rel
improv baselin compar placebo rel compar efficaci
seen kalydeco tezacaftor popul compani also studi corrector
potenti clinic tripl combo demonstr
wildtyp activ homozyg hbe cell level activ similar better
demonstr vertex galapagos/abbvi tripl combo unclear moment whether vitro data
translat human efficaci linearli proteostasi combo could command efficaci advantag
vertex galapagos/abbvi compani plan push tripl combo clinic first half
proof-of-concept data follow second half
upcom catalyst includ data phase ii tripl combin studi first half
initi phase studi tripl combo first half initi phase studi
tripl combo initi proof-of-concept data vertex program outsid cystic fibrosi next one
risk market perform rate vertex includ stronger competit data cf inabl develop
tripl combo therapi setback relat clinic preclin busi develop activ
incom world-wide duo combo worldiwid sale incl orkambi cf tripl combo world-wide sales- hcv net royalti collabor total restructur expens total oper interest exchang convert notes- incom pre-tax incom net incom loss attribut non-controlling net incom loss atribut vertex non- incom compens compens transaction/hcv-rel septemb transactions- intang asset impair charg net tax- collabor crispr- restructur one-tim total averag share outstand averag share outstand compani report william blair compani incorporatedincom statement dollar thousand william blair
compani report exhibit incorporatedabsolut chang lung function time william blair
dollar thousand drugpeak salesstag ofdevelopmentestim launch dateprob commercializationpercentag sale companyprobability-adjust npvvalu per sharepercentag fair valuekalydeco cystic fibrosi gate marketedfebruari combo cystic homozyg market orkambi pre-registr kalydeco/tezacaftor juli combofor cystic phase year-end present valu addit gain loss fair includ cost directli relat program abovesourc compani report william blair compani estimatesexhibit incorporatedsum-of-part fair valuesourc william blair compani estimatesexhibit incorporatedcyst fibrosi market model summari import disclosur
